Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Zhou, Jiebai ^a   Min, Zhihui ^b,c   Zhang, Ding ^a   Wang, William ^d   Marincola, Francesco ^e   Wang, Xiangdong ^a,b,c  

^a Department of Pulmonary Medicine ^*  (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Lung cancer; Lymphocytes; Microenvironment; Regulatory B cells; Regulatory T cells

Indexed keywords

CD19 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RANTES; TRANSFORMING GROWTH FACTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL POLARITY; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LUNG CANCER; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTOPOIESIS; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; TUMOR IMMUNITY; DONOR; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LUNG TUMOR; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

B-LYMPHOCYTES, REGULATORY; CELL LINE, TUMOR; CHEMOKINE CCL3; COCULTURE TECHNIQUES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; NF-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE DONORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84920754201     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0304-0     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2003, 63:11-30.
2. World Health Organization: The global burden of disease: 2004 update. In [http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/]
3. Johansson M, Denardo DG, Coussens LM: Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
4. Riddell SR: Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 2004, 200:1533-1537.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
6. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y: Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293.
7. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
8. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T: CD4 + CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005, 14:1269-1273.
9. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001, 31:1122-1131.
10. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr: Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
11. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K: Tumorinfiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010, 5:585-590.
12. Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V: FOXP3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 2011, 6:432-438.
13. Lundy SK: Killer B lymphocytes: the evidence and the potential. Inflamm Res 2009, 58:345-357.
14. Vitale G, Mion F, Pucillo C: Regulatory B cells: evidence, developmental origin and population diversity. Mol Immunol 2010, 48:1-8.
15. Watanabe R, Ishiura N, Nakashima H, Kuwano Y, Okochi H, Tamaki K, Sato S, Tedder TF, Fujimoto M: Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. J Immunol 2010, 184:4801-4809.
16. DiLillo DJ, Matsushita T, Tedder TF: B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010, 1183:38-57.
17. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4 T cells to T-regulatory cells. Cancer Res 2011, 71:3505-3515.
18. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
19. Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ: Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007, 322:57-69.
20. Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE, Gibot S: The relationship between CD4 + CD25 + CD127-regulatory T cells and inflammatory response and outcome during shock states. Crit Care 2010, 14:R19.
21. Iwata Y, Matsushita T, Horikawa M, DiLillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541.
22. Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B-cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008, 28:639-650.
23. Woo EY, Yeh H, Chu CS, Schleinger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168:4272-4276.
24. Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Ge Y, Johnson DE, Ju S, Shu Y: CD13 + CD4 + CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 2009, 8:2578-2585.
25. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 2006, 438:820-827.
26. Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
27. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, Solomon M, Lee S, Nanan R, Fazekas de Saint Groth B: Persistence of naïve CD45RA + regulatory T cells in adult life. Blood 2006, 107:2830-2838.
28. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res 2002, 8:3803-3812.
29. Konishi T, Okabe H, Katoh H, Fujiyama Y, Mori A: Macrophage inflammatory protein-1 alpha expression in non-neoplastic and neoplastic lung tissue. Vichows Arch 1996, 428:107-111.
30. Wang XD, Peer D, Petersen B: Molecular and Cellular Therapies: New challenges and opportunities. Mol Cell Therap 2013, 1:1.
31. Wu XD, Chen LN, Wang XD: Network biomarkers, interaction networks and dynamical network biomarkers in respiratory diseases. Clin Transl Med 2014, 3:16.
32. Zhu Z, Wang DC, Popescu LM, Wang XD: Single-cell transcriptome in the identification of disease biomarkers: opportunities and challenges. J Transl Med 2014, 12:212.
33. Wang XD: Role of clinical bioinformatics in the development of networkbased Biomarkers. J Clin Bioinforma 2011, 1:28.
34. Wu DJ, Zhu BJ, Wang XD: Metabonomics-based omics study and atherosclerosis. J Clin Bioinforma 2011, 1:30.
35. Wang XD, Liotta L: Clinical bioinformatics: a new emerging science. J Clin Bioinforma 2011, 1:1.
36. Taylor MA, Schiemann WP: Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Therap 2014, 2:30.
37. Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G: MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Therap 2014, 2:16.
38. Frantzi M, Bhat A, Latosinska A: Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med 2014, 3:7.